PDCD1 and neoplasm: Several studies have shown that the integration of PD-1-mediated inhibitory signaling into CAR-T significantly improves the function of conventional CAR-T, and it even may have an almost equivalent or better anti-tumor effect and a lower side effect compared with the CAR-T plus PD-1 antibody (72, 145, 146).